EP4096409A1 - Procédé comprenant des bactériophages pour la réduction de la population d'au moins une espèce bactérienne adipogène, et bactériophages et leur utilisation - Google Patents

Procédé comprenant des bactériophages pour la réduction de la population d'au moins une espèce bactérienne adipogène, et bactériophages et leur utilisation

Info

Publication number
EP4096409A1
EP4096409A1 EP21703367.9A EP21703367A EP4096409A1 EP 4096409 A1 EP4096409 A1 EP 4096409A1 EP 21703367 A EP21703367 A EP 21703367A EP 4096409 A1 EP4096409 A1 EP 4096409A1
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
adipogenic
bacterial species
bacteriophages
bacteriophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21703367.9A
Other languages
German (de)
English (en)
Inventor
Oxana Karpf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP4096409A1 publication Critical patent/EP4096409A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/40—Viruses, e.g. bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • antibiotics which are currently considered conventional therapy for humans and animals.
  • Such substances are characterized by a broad spectrum of activity, as they target molecular structures or molecules of the bacteria, which occur in a large number of types of bacteria.
  • a wide range of bacteria can be reduced or eliminated by means of antibiotics.
  • the disadvantage here is that the initially mentioned commensal or symbiotic bacteria are also killed by the use of antibiotics, which can lead to consequential damage to humans, animals and / or the environment.
  • damage to commensal and / or symbiotic bacteria can result in a shift in the balance of the microbiome in favor of pathogenic microorganisms (e.g. bacteria and / or fungi), which, for example, can lead to a condition lasting several months with often serious consequences .
  • nucleic acid sequence which encodes a nucleic acid molecule that is at least 50% identical to the nucleic acid molecule which is encoded by the nucleic acid sequences from i); and iii. a nucleic acid sequence which codes for at least one antibacterial polypeptide; and iv. a nucleic acid sequence which encodes a polypeptide that is at least 50% identical to a polypeptide which is encoded by the nucleic acid sequences from iii); and V.
  • the term “population” is known to a person skilled in the art and generally relates to the totality of all individuals of the same species that occur in a certain area or in a certain area of the environment. In the context of the invention, the population relates to the entirety of the bacteria of at least one adipogenic bacterial species.
  • the terms “bacterium” and “bacteria” can be understood by a person skilled in the art as interchangeable synonyms and relate to representatives of one or more types of bacteria.
  • nucleic acid and nucleic acid sequences encode two or more nucleic acid molecules, polypeptides and / or fragments thereof, the nucleic acid preferably 2, 3, 4, 5, 6, 7, 8, 9 , 10, 11, 12, 13, 14, 15, 16, 17, 18,
  • Promoter and / or nucleic acid linked to a regulatory element and b) instructions for carrying out the procedure.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de réduction de la population d'au moins une espèce bactérienne adipogène, ledit procédé comprenant les étapes suivantes consistant à : a) préparer un échantillon biologique qui contient des bactéries d'au moins une espèce bactérienne adipogène ; et b) préparer des bactériophages d'au moins une espèce bactériophage qui sont spécifiques à au moins une espèce bactérienne adipogène et qui comprennent au moins un acide nucléique qui est fonctionnellement lié à un promoteur et/ou à un élément régulateur ; et c) mettre en contact l'échantillon biologique avec les bactériophages et incuber l'échantillon avec les bactériophages, l'incubation étant réalisée jusqu'à ce que la population de l'espèce bactérienne adipogène soit réduite d'au moins 70 %. L'invention concerne également des bactériophages et leur utilisation.
EP21703367.9A 2020-01-27 2021-01-20 Procédé comprenant des bactériophages pour la réduction de la population d'au moins une espèce bactérienne adipogène, et bactériophages et leur utilisation Pending EP4096409A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102020101859.2A DE102020101859A1 (de) 2020-01-27 2020-01-27 Verfahren zur Reduktion der Population mindestens einer adipogenen Bakterienart umfassend Bakteriophagen sowie Bakteriophagen und deren Verwendung
PCT/EP2021/051212 WO2021151759A1 (fr) 2020-01-27 2021-01-20 Procédé comprenant des bactériophages pour la réduction de la population d'au moins une espèce bactérienne adipogène, et bactériophages et leur utilisation

Publications (1)

Publication Number Publication Date
EP4096409A1 true EP4096409A1 (fr) 2022-12-07

Family

ID=74553780

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21703367.9A Pending EP4096409A1 (fr) 2020-01-27 2021-01-20 Procédé comprenant des bactériophages pour la réduction de la population d'au moins une espèce bactérienne adipogène, et bactériophages et leur utilisation

Country Status (8)

Country Link
US (1) US20230145361A1 (fr)
EP (1) EP4096409A1 (fr)
JP (1) JP2023518653A (fr)
CN (1) CN115334886A (fr)
AU (1) AU2021213377A1 (fr)
CA (1) CA3165924A1 (fr)
DE (1) DE102020101859A1 (fr)
WO (1) WO2021151759A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102020128879A1 (de) * 2020-11-03 2022-05-05 Oxana Karpf Verfahren zur Reduktion der Population mindestens einer intestinalen und/oder gastrointestinalen Bakterienart umfassend Bakteriophagen sowie Bakteriophagen und deren Verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004041156A2 (fr) 2002-01-23 2004-05-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health Andhuman Services Procede de determination de la sensibilite a un bacteriophage
US20130195886A1 (en) * 2011-11-27 2013-08-01 The Regents Of The University Of Colorado, A Body Corporate Methods for Fructanase and Fructokinase Inhibition
FR3014310B1 (fr) * 2013-12-05 2018-02-23 International Nutrition Research Company Dispositifs pour reguler l'alimentation des operes bariatriques
IL310108A (en) * 2015-05-06 2024-03-01 Snipr Tech Ltd Changing bacterial populations and microbiota adaptation
FR3052361B1 (fr) * 2016-06-09 2019-08-23 Centre National De La Recherche Scientifique Diethers d’archaea lipides synthetiques
EP3595689A4 (fr) * 2017-03-14 2020-12-09 Brigham Young University Méthodes et compositions pour traiter l'obésité, l'inflammation ou des troubles métaboliques avec des bactériophages
AU2019208460A1 (en) * 2018-01-19 2020-09-03 Cytophage Technologies Inc. Genetically engineered bacteriophage

Also Published As

Publication number Publication date
CN115334886A (zh) 2022-11-11
JP2023518653A (ja) 2023-05-08
DE102020101859A1 (de) 2021-07-29
US20230145361A1 (en) 2023-05-11
AU2021213377A1 (en) 2022-08-25
CA3165924A1 (fr) 2021-08-05
WO2021151759A1 (fr) 2021-08-05

Similar Documents

Publication Publication Date Title
JP6856968B2 (ja) 自閉症スペクトラム障害および関連する症候を治療するための方法
CN109803667A (zh) 用于治疗溃疡性结肠炎的方法
CN109789172A (zh) 用于难辨梭菌治疗的组合物和方法
Boovaragamoorthy et al. Clinically important microbial diversity and its antibiotic resistance pattern towards various drugs
JP2022547330A (ja) 自閉症スペクトラム障害を治療するための組成物および方法
Dinh et al. Management of established pressure ulcer infections in spinal cord injury patients
EP4096409A1 (fr) Procédé comprenant des bactériophages pour la réduction de la population d'au moins une espèce bactérienne adipogène, et bactériophages et leur utilisation
US20240173360A1 (en) Compositions and methods for treating epilepsy and related disorders
Hirsh et al. The effect of tetracycline upon establishment of Escherichia coli of bovine origin in the enteric tract of man
Tarmakova et al. Impact of phytobacterial agent on the toxic damage to the liver and ileum of white rats
EP4240384A1 (fr) Procédé de réduction de la population d'au moins une espèce bactérienne intestinale et/ou gastro-intestinale comprenant des bactériophages, et bactériophages et leur utilisation
DE102017113263A1 (de) Pharmazeutische Zusammensetzung enthaltend Bakterienstämme aus der Familie der Lactobacillaceae und Molke
RU2367454C1 (ru) Средство интимной гигиены "фемивит"
DE69634542T2 (de) Verwendung von einer dehydrierten zubereitung von propionischen bakterien zur herstellung einer diätetischen zusammensetzung zur verbesserung des biologischen gleichgewichts der darmflora
DE3938233A1 (de) Mittel gegen venenentzuendungen bei menschen
Zuscik et al. Targeting the Gut Microbiome to Treat Post Traumatic Osteoarthritis
Sar et al. Effects of B. bacteriovorus (ATCC™ 1534) Injection on Some Serum Chemistry Parameters in Rats Injected with P. multocida
Li et al. P141 GREEN TEA POLYPHENOL EPIGALLOCATECHIN-3-GALLATE DIFFERENTIALLY MODULATES ENDOPLASMIC RETICULUM STRESS-MEDIATED WOUND HEALING PROCESS IN SUBEPITHELIAL MYOFIBROBLASTS
EP3973971A1 (fr) Compositions pharmaceutique comprenant un probiotique
WO2022189010A1 (fr) Méthodes et compositions pour le traitement et la prévention d'infections des voies urinaires
DE102021000073A1 (de) Pharmazeutisch antimikrobielles Kombinationspräparat auf Zink - Nystatin - Wirkstoffbasis als immunologisch-hybridwirkendes therapeutisch präventives Arzneimittel zur oralen Einnahme
US20180099013A1 (en) Compositions and Methods for Treating Chronic Fatigue Syndrome and Related Disorders
DE102004055891B4 (de) Gemische von Schlangengiften zur Krankheitsbekämpfung
DE4432262A1 (de) Präparatkombination zur Therapie und Prophylaxe von Erkrankungen des Verdauungstraktes
van Nuenen et al. The effect of anti-TNF-α antibody therapy in Crohn’s disease on composition and activity of faecal microbiota: a pilot study

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220809

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)